Title |
Chlorproguanil−Dapsone−Artesunate versus Artemether−Lumefantrine: A Randomized, Double-Blind Phase III Trial in African Children and Adolescents with Uncomplicated Plasmodium falciparum Malaria
|
---|---|
Published in |
PLOS ONE, August 2009
|
DOI | 10.1371/journal.pone.0006682 |
Pubmed ID | |
Authors |
Zul Premji, Rich E. Umeh, Seth Owusu-Agyei, Fabian Esamai, Emmanuel U. Ezedinachi, Stephen Oguche, Steffen Borrmann, Akintunde Sowunmi, Stephan Duparc, Paula L. Kirby, Allan Pamba, Lynda Kellam, Robert Guiguemdé, Brian Greenwood, Stephen A. Ward, Peter A. Winstanley |
Abstract |
Chlorproguanil-dapsone-artesunate (CDA) was developed as an affordable, simple, fixed-dose artemisinin-based combination therapy for use in Africa. This trial was a randomized parallel-group, double-blind, double-dummy study to compare CDA and artemether-lumefantrine (AL) efficacy in uncomplicated Plasmodium falciparum malaria and further define the CDA safety profile, particularly its hematological safety in glucose-6-phosphate dehydrogenase (G6PD) -deficient patients. |
Mendeley readers
Geographical breakdown
Country | Count | As % |
---|---|---|
United Kingdom | 4 | 3% |
Vietnam | 1 | <1% |
Switzerland | 1 | <1% |
Brazil | 1 | <1% |
Belgium | 1 | <1% |
Unknown | 123 | 94% |
Demographic breakdown
Readers by professional status | Count | As % |
---|---|---|
Researcher | 19 | 15% |
Student > Master | 18 | 14% |
Student > Bachelor | 14 | 11% |
Other | 12 | 9% |
Student > Ph. D. Student | 12 | 9% |
Other | 30 | 23% |
Unknown | 26 | 20% |
Readers by discipline | Count | As % |
---|---|---|
Medicine and Dentistry | 42 | 32% |
Biochemistry, Genetics and Molecular Biology | 14 | 11% |
Agricultural and Biological Sciences | 13 | 10% |
Pharmacology, Toxicology and Pharmaceutical Science | 7 | 5% |
Nursing and Health Professions | 6 | 5% |
Other | 20 | 15% |
Unknown | 29 | 22% |